Congress Asset Management Co. Purchases 24,306 Shares of Integer Holdings Co. (NYSE:ITGR)

Congress Asset Management Co. boosted its position in Integer Holdings Co. (NYSE:ITGR - Free Report) by 4.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 522,656 shares of the medical equipment provider's stock after purchasing an additional 24,306 shares during the period. Congress Asset Management Co. owned approximately 1.55% of Integer worth $61,679,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in the company. Portside Wealth Group LLC increased its position in shares of Integer by 14.8% during the first quarter. Portside Wealth Group LLC now owns 3,125 shares of the medical equipment provider's stock worth $369,000 after acquiring an additional 403 shares during the period. Contravisory Investment Management Inc. grew its holdings in Integer by 103.9% in the first quarter. Contravisory Investment Management Inc. now owns 1,413 shares of the medical equipment provider's stock worth $167,000 after purchasing an additional 720 shares during the last quarter. Heritage Family Offices LLP grew its holdings in Integer by 8.2% in the first quarter. Heritage Family Offices LLP now owns 3,283 shares of the medical equipment provider's stock worth $387,000 after purchasing an additional 250 shares during the last quarter. GAMMA Investing LLC grew its holdings in Integer by 8,697.6% in the first quarter. GAMMA Investing LLC now owns 78,123 shares of the medical equipment provider's stock worth $92,190,000 after purchasing an additional 77,235 shares during the last quarter. Finally, AdvisorNet Financial Inc purchased a new position in Integer in the first quarter worth $28,000. Institutional investors own 99.29% of the company's stock.

Integer Stock Up 0.3%

ITGR stock opened at $121.25 on Friday. The stock has a market capitalization of $4.23 billion, a P/E ratio of 36.09, a P/E/G ratio of 1.72 and a beta of 0.98. The firm has a 50-day simple moving average of $118.81 and a 200-day simple moving average of $128.12. The company has a quick ratio of 2.09, a current ratio of 2.95 and a debt-to-equity ratio of 0.62. Integer Holdings Co. has a 52 week low of $104.93 and a 52 week high of $146.36.

Integer (NYSE:ITGR - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The medical equipment provider reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.04. Integer had a net margin of 6.92% and a return on equity of 11.65%. The company had revenue of $437.39 million during the quarter, compared to analysts' expectations of $428.51 million. During the same quarter in the prior year, the company earned $1.14 EPS. Integer's revenue was up 7.3% compared to the same quarter last year. Equities analysts forecast that Integer Holdings Co. will post 6.01 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Joseph W. Dziedzic sold 338,975 shares of the stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $123.17, for a total transaction of $41,751,550.75. Following the completion of the transaction, the chief executive officer now owns 47,000 shares of the company's stock, valued at approximately $5,788,990. This trade represents a 87.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Donald J. Spence sold 14,739 shares of the stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $120.38, for a total transaction of $1,774,280.82. Following the transaction, the director now directly owns 18,781 shares of the company's stock, valued at $2,260,856.78. The trade was a 43.97% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 362,434 shares of company stock worth $44,577,115. Company insiders own 2.16% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on ITGR shares. Oppenheimer downgraded shares of Integer from an "outperform" rating to a "market perform" rating in a research note on Friday, February 21st. KeyCorp lowered their price objective on shares of Integer from $154.00 to $145.00 and set an "overweight" rating for the company in a research note on Monday, April 21st. Benchmark lowered their price objective on shares of Integer from $150.00 to $140.00 and set a "buy" rating for the company in a research note on Friday, April 25th. Raymond James boosted their target price on shares of Integer from $145.00 to $150.00 and gave the company an "outperform" rating in a research report on Friday, April 25th. Finally, Citigroup upgraded shares of Integer from a "hold" rating to a "strong-buy" rating and boosted their target price for the company from $133.00 to $140.00 in a research report on Thursday, May 22nd. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $145.00.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.